IMPORTANT SAFETY INFORMATION

Zynlonta® loncastuximab tesirine
for injection, for intravenous use • 10mg

for patients taking ZYNLONTA®▼ (loncastuximab tesirine)

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See enclosed for details.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the patient leaflet. Side effects can be reported directly to Health Products Regulatory Authority, HPRA Pharmacovigilance, website www.hpra.ie. Side effects should also be reported to Swedish Orphan Biovitrum Ltd via email at medical.info.uk@sobi.com or by calling +44 (0) 800 111 4754. By reporting side effects you can help provide more information on the safety of this medicine.

PATIENT ALERT CARD

INFORMATION FOR PATIENTS

This patient alert card contains important safety information that you need to be aware of during treatment with ZYNLONTA.

Read the Patient Information Leaflet (PIL) for more information.

Please always keep this card with you during treatment and show this card to any healthcare professional involved in your care.

- Treatment with ZYNLONTA can cause photosensitivity reactions (skin reactions after exposure to sunlight) through exposure to artificial sunlight, direct and indirect sunlight (such as through glass windows in vehicles and public transportation) including:
  - sunburn-like reactions such as skin peeling and irritation following exposure to light
  - itchy rash
  - blistering of skin
  - darker skin patches
  - irritation, swelling, pain

- **You must protect skin from exposure to sunlight by wearing sun-protective clothing and/or the use of sunscreen products during the entire treatment period**
- If you experience any of these skin reactions, you should immediately call your treating healthcare professional or seek emergency medical care and show this card right away

CONTACT DETAILS

Patient name:

_____

Prescribing hospital:

_____

Prescribing Physician's name:

_____

Prescribing Physician's telephone number:

_____

INFORMATION FOR HEALTHCARE PROFESSIONALS

Please note that this patient is receiving treatment with ZYNLONTA (loncastuximab tesirine) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL).

- ZYNLONTA can cause photosensitivity reactions, including sunburn-like reactions such as skin peeling and irritation following exposure to light, itchy rash, blistering of skin, darker skin patches, irritation, swelling, pain
- ZYNLONTA should be withheld for severe (Grade 3) cutaneous reactions until resolution
- Dermatologic consultation should be considered
- Contact prescribing doctor (left) as soon as possible

REPORTING OF SUSPECTED ADVERSE REACTIONS:

▼Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, website www.hpra.ie.

Adverse reactions/events should also be reported to Swedish Orphan Biovitrum Ltd via email at medical.info.uk@sobi.com or by calling +44 (0) 800 111 4754.

For more information about ZYNLONTA, please refer to the full Summary of Product Characteristics or alternatively e-mail medical.info.uk@sobi.com or call +44 (0) 800 111 4754.

Swedish Orphan Biovitrum Ltd,
Suite 2, Riverside 3, Granta Park,
Great Abington,
Cambridgeshire, CB21 6AD
www.sobi.com/ireland/en

NP-28942 September 2023

sobi